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Abstract: The preparation of N-protected amino/peptide α-cyano-
methyl ketones through cyanation of the corresponding α-bromo-
methyl ketones is described. The utility of the resulting α-
cyanomethyl ketones in the synthesis of 3-substituted-5-amino-1H-
pyrazoles has also been demonstrated. In both steps a wide range of
N-protected amino/peptide acids has been employed and the prod-
ucts are obtained in good yield. The enantiomeric purity of both the
α-cyanomethyl ketones and pyrazoles were confirmed by chiral
HPLC analysis of the corresponding Z-protected D- and L-Ala-OH
as model substrates. The synthesis of peptide pyrazolecarbox-
amides is also delineated.
Key words: peptidomimetics, amino acid mimics, ketones, pyr-
azole
An important aspect of peptidomimetic design involves
the use of suitable building blocks. To this end, either the
-NH2 or -COOH group of enantiopure α-amino acids are
converted into the desired functionality. Among them,
azides,1 isonitriles,2 nitriles,3 and acetylenes4 have been
generated at the amine or acid termini of α-amino acids.
Employing these key constituents, the insertion of scaf-
folds such as a tetrazole, thiazole, imidazole, triazole, and
oxadiazole in place of the peptide bond has also been a
subject of interest, particularly for studying the physio-
chemical and biological properties of peptides (Figure
1).5–8
Figure 1  Selected examples of N-heterocycles derived from amino
acids
N-Protected α-aminoalkyl-α′-halomethyl ketones9 have
emerged as attractive targets for the design of peptidomi-
metics.10–12 Our group has developed a simple route for
the preparation of N-protected α-aminoalkyl-α′-halo-
methyl ketones and employed them for the construction of
thiazole,13 selenazole,14 and triazole15 tethered peptidomi-
metics (Scheme 1).
In the present letter we describe the synthesis of N-ure-
thane protected α-aminoalkyl-α′-cyanomethyl ketones
and their utility in the synthesis of amino acid derived 3-
substituted 5-amino-1H-pyrazoles. The α-cyanomethyl
ketone is an important scaffold that is found in many phar-
maceutical compounds16 with a broad spectrum of biolog-
ical activity.17,18 Sauve et al. reported amino acid derived
α-cyanomethyl ketones and carboxy group modified di-
peptides.19 Boc/Ac-protected Phe/Leu-Phe derived cya-
nomethyl ketones were synthesized through alkylation of
Boc/Ac-amino thioamide with methyl triflate and the re-
sulting intermediate was treated with a nucleophile. N-
Acetyl protected cyanomethyl ketones have also been pre-
pared by the reaction of activated carboxylic acids and the
carbanion of tert-butyl cyanoacetate, and the resulting
enols were then subjected to hydrolysis followed by de-
carboxylation.20 α-Cyanomethyl ketones derived from
N,N′-bisbenzyl protected benzyl phenyl alaninate was
prepared by the reaction of MeCN and NaNH2.21 Some of
the above approaches either require a cumbersome proto-
col or are incompatible with the use of urethane-type pro-
tecting groups. We describe herein a convenient method
for the synthesis of urethane-protected α-cyanomethyl ke-
tones and their conversion into N-Boc/Z-protected α-ami-
noalkyl-5-amino pyrazoles. Pyrazole22 derivatives of α-
amino acids have received considerable attention because
of their diverse range of biological properties such as po-
tent angiotensin II antagonist activity both in vitro and in
vivo,23 anti-hypertensive, anti-bacterial, and anti-inflam-
matory activity,24 muscle relaxant properties, and inhibi-
tion of cyclin dependent kinases.25 They have also been
used as building blocks for the synthesis of peptidomimet-
ics.26,27
The required urethane-protected α-aminoalkyl-α′-bromo-
methyl ketone precursors were prepared by using a two-
step procedure reported by our group.13 A similar ap-
proach was employed for the preparation of bromomethyl
ketones containing the Boc-protected compounds with
suitable modifications.28 In all cases, bromomethyl ke-
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tones were obtained as stable solids without the need for
column purification. The resulting α-bromomethyl ke-
tones were then converted into α-cyanomethyl ketones.
We initially investigated the use of several cyanating re-
agents by using different solvents; the results are summa-
rized in Table 1. Boc-Ala-[CH2Br] 2a (Scheme 2) was
used as a model substrate to optimize the reaction condi-
tions, with the progress of the reaction being monitored by
TLC. Treatment of 2a with TMSCN in MeOH failed to
give 3a at room temperature (Table 1, entry 1), but under
reflux conditions the product was obtained in 20% yield
(Table 1, entry 2). We then explored the use of NaCN,
HgCN, K3Fe(CN)6 and KCN at room temperature in
MeOH (Table 1, entries 3–6). KCN turned out to be the
most useful to obtain 3a. Furthermore, we examined a
range of solvents with the aim of stabilizing the reaction
conditions and found that use of THF and CH3CN led to
the formation of 3a in moderate yield (Table 1, entries 7
and 8), DMF and DMSO gave acceptable yields of 3a (68
and 72% respectively; Table 1, entries 9 and 10), but the
use of MeOH provided an excellent yield of 3a at room
temperature (Table 1, entry 6).
Scheme 2 Synthesis of N-protected α-aminoalkyl or peptidyl cyano-
methyl ketones 3
Under the optimized conditions, reactant 2a was com-
pletely consumed, as evidenced by IR and RP-HPLC
analysis. The disappearance of the strong IR absorption
band at 1730 cm–1 for the α-bromomethyl ketone 2a and
the appearance of strong bands at 1650 and 2243 cm–1 for
the carbonyl and adjacent nitrile groups, respectively,
confirmed the formation of 3a. The protocol was further
applied to various N-protected amino/peptide α-bromo-
methyl ketones to obtain the corresponding cyanomethyl
ketones (Table 2).29 The procedure worked well even for
amino acids Ser and Thr, which contain free hydroxyl
groups (Table 2, entries 9, 13, and 15). 
Next, we turned our attention to the synthesis of a hitherto
unreported class of Nα-Boc/Z-aminoalkyl-5-amino pyr-
azoles.30 The 3-substituted 5-amino-1H-pyrazole deriva-
tives 4 were prepared by reaction of α-cyanomethyl
ketones 3 with hydrazine hydrate under reflux in MeOH
(Scheme 3). In a typical experiment, Boc-Ala-[CH2CN]
3a was added to a solution of 99–100% hydrazine hydrate
in MeOH. The reaction mixture was heated to reflux at
40 °C for approximately two hours. After completion of
the reaction (TLC analysis), the solvent was evaporated
under reduced pressure and the residue was purified by
column chromatography to afford 4a.31 Several Boc and
Z-protected α-aminoalkyl-α′-cyanomethyl ketones were
Scheme 1 Various transformations of N-protected α-aminoalkyl-α′-halomethyl ketones reported by our group
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Table 1 Screening of Cyanating Agents and Solvents for the Synthe-
sis of 3aa
Entrya Cyanating reagent Solvent Temp 
(°C)
Yield 
(%)b
1 TMSCN MeOH 25 –
2 TMSCN MeOH 60 20
3 NaCN MeOH 25 38
4 HgCN MeOH 25 49
5 K3Fe(CN)6 MeOH 25 55
6 KCN MeOH 25 91
7 KCN THF 35 40
8 KCN MeCN 25 45
9 KCN DMF 40 68
10 KCN DMSO 40 72
a Boc-Ala-CH2Br 2a (1.0 mmol) was treated with cyanating reagent 
(1.2 mmol).
b Yield of isolated product 3a after column purification.
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converted into their respective pyrazole derivatives 4a–i
in good yield and purity (Table 3).
Scheme 3 Synthesis of N-protected 3-substituted 5-amino-1H-pyr-
azoles 4
Similarly, two examples of Nα-Boc/Z-protected peptidyl
3-substituted 5-amino-1H pyrazoles 4j–k were also pre-
pared (Figure 2). Both cyanomethyl ketones and pyrazole
derivatives were characterized by mass, IR and NMR
analyses. 
Figure 2 Dipeptidyl pyrazoles synthesized 
In order to gain insight into the possibility of racemiza-
tion, enantiomeric Z-protected D- and L-Ala-OH were
Table 2 List of Nα-Z/Boc-Protected α-Cyanomethyl Ketones 3a–r
Entry Product 3 [α]D25 
(c 1, CHCl3)
Yield 
(%)a
1 3a –14.2 89
2 3b –12.1 88
3 3c –21.2 90
4 3d –15.3 87
5 3e –13.4 89
6 3f –16.7 90
7 3g –18.3 91
8 3h +21.6 90
9 3i –22.1 88
10 3j –12.5 80
11 3k –13.9 78
12 3l –17.2 89
13 3m –14.8 79
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converted into cyanomethyl ketones and pyrazoles under
the developed reaction conditions, and their enantiomeric
excess was determined by chiral HPLC analysis.32 As
shown in Figure 3, compounds 3g and 3h showed single
peaks with retention times of 28.1 and 22.5 min, respec-
tively.
In contrast, the constituents of the racemic mixture of 3g
and 3h were separated with retention times of 27.8 and
21.9 min. Similarly, HPLC profiles for pyrazoles 4g and
4h showed retention times of 16.9 and 10.1 min, respec-
tively. Thus, these results confirm that both α-cyanometh-
yl ketones and pyrazoles were prepared in optically pure
form.
Finally, the synthesis of pyrazole-linked dipeptidomimet-
ics was undertaken. Pyrazolecarboxamide derivatives are
known for their use in the treatment of pain and
inflammation33 and also play a vital role in the β-sheet sta-
bilization of peptides.34 Thus, pyrazoles 4 were employed
to synthesize peptide-derived pyrazolecarboxamides 6.
As a test case, a solution of Fmoc-Val-Cl35 in anhydrous
THF, Boc-Ala-pyrazole amine 4a and NMM were reacted
at 0 °C. The coupling was found to be complete in three
hours, as observed by TLC analysis (Scheme 4). 
Scheme 4 Synthesis of pyrazole-tethered peptidomimetics
The desired N,N′-orthogonally protected dipeptidomimet-
ic 6a36 was isolated in 88% after column purification. As
Table 3  Data for 3-Substituted 5-Amino-1H-pyrazole Derivatives 4a–i
4 PG R HRMS [M + Na]+ Yield (%)a [α]D25 (c 1, CHCl3)
Calcd Found 
4a Boc Me 249.1327 249.1230 85 –12.1
4b Boc i-Pr 277.1640 277.1643 88 –15.3
4c Boc Bn 325.1638 325.1640 92 –17.2
4d Boc i-Bu 291.1793 291.1791 94 –14.5
4e Boc CH2OH 355.1748 355.1746 92 –10.9
4f Z CH2COOt-Bu 505.1849 253.1852 91 –29.5
4g Z Me 359.1481 359.1484 90 –13.5
4h Z Meb 248.1241 248.1249 88 –14.9
4i Z CH(CH3)OH 445.1856 455.1852 87 –16.2
a Isolated yield.
b Z-D-Ala-OH was used as starting compound.
Figure 3 Chiral HPLC analysis.32 Chromatograms shown are: (a) Z-L-Ala-CH2CN 3g; (b) Z-D-Ala-CH2CN 3h; (c) Prepared 1:1 mixture of 3g
and 3h; (d) Z-L-Ala-pyrazole 4g; (e) Z-D-Ala-pyrazole 4h; (f) Prepared 1:1 mixture of 4g and 4h.
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shown in Figure 4, the same procedure was extended to
the synthesis of compounds 6b–e.
In summary, a simple and easily accessible route has been
established for the synthesis of enantiopure N-urethane-
protected amino acid/peptidyl cyanomethyl ketones. The
resulting cyanomethyl ketones were utilized for the con-
struction of amino acid derived 3-substituted-5-amino-
1H-pyrazoles. The protocol has also been extended to pre-
pare five N,N′-orthogonally protected pyrazolecarbox-
amide tethered peptidomimetics in good yield.
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1.0, CHCl3); Rf = 0.4 (EtOAc–hexane, 3:7); IR (neat): 1650, 
1745, 2243 cm–1; 1H MR (CDCl3, 400 MHz): δ = 1.31 (d, 
J = 6.0 Hz, 3 H), 1.35 (s, 9 H), 3.19 (s, 2 H), 4.23 (m, 1 H), 
6.8 (br, 1 H); 13C NMR (CDCl3, 100 MHz): δ = 13.6, 28.0, 
28.7, 56.4, 80.1, 116.5, 155.4, 205.4; HRMS: m/z [M + Na]+ 
calcd for C10H16N2O3: 235.1059; found: 235.1062
Compound 3o: Yield: 82%; brownish gum; [α]D25 –15.7 (c 
1.0, CHCl3); Rf = 0.4 (EtOAc–hexane, 5:5); IR (neat): 1658, 
1718, 1741, 2231 cm–1; 1H NMR (CDCl3, 400 MHz): δ = 
0.99 (d, J = 4.8 Hz, 6 H), 1.62 (m, 2 H), 1.78 (m, 1 H), 2.64 
(s, 1 H), 3.70 (s, 2 H), 3.78 (m, 2 H), 3.84 (m, 1 H), 4.64 (m, 
1 H), 5.12 (m, 2 H), 5.93 (br, 1 H), 7.12 (m, 5 H); 13C NMR 
(CDCl3, 100 MHz): δ = 22.0, 22.4, 28.4, 40.4, 47.2, 57.3, 
63.4, 65.1, 116.2, 127.1, 127.3, 128.3, 140.2, 155.5, 170.8, 
207.2; HRMS: m/z [M + Na]+ calcd for C19H25N3O5: 
398.1794; found: 398.1792
(30) Goodman, M.; Felix, A.; Moroder, L.; Toniolo, C. Houben-
Weyl: Synthesis of Peptides & Peptidomimetics; Vol. E22c; 
Georg Thieme Verlag: Stuttgart, New York, 2003, 663–689.
(31) Preparation of Boc-Ala-5-amino-pyrazole 4a; Typical 
Procedure: To a solution of Nα-protected Boc-Ala-
[CH2CN] 3a (1.8 mmol, 0.4 g) in MeOH (5 mL), hydrazine 
hydrate (14 mmol, 0.7 mL) was added. The reaction mixture 
was heated at reflux at 40 °C for 2 h (progress monitored by 
TLC). After cooling, the solvent was removed under reduced 
pressure to obtain the crude product, which was purified by 
column chromatography (silica gel 100–200 mesh; CHCl3–
MeOH, 9:1).
Compound 4a: Yield: 85%; yellowish gum; [α]D25 –12.1 (c 
1.0, CHCl3); Rf = 0.3 (CHCl3–MeOH, 9:1); IR (neat): 1740, 
2874, 3429 cm–1; 1HNMR (CDCl3, 400 MHz): δ = 1.34 (d, 
J = 8.1 Hz, 3 H), 1.40 (s, 9 H), 3.82 (m, 1 H), 5.22 (br, 2 H), 
5.80 (s, 1 H), 6.21 (br, 1 H), 9.40 (br, 1 H); 13C NMR 
(CDCl3, 100 MHz): δ = 19.2, 29.0, 48.3, 80.1, 96.3, 141.2, 
155.1, 155.8; HRMS: m/z [M + Na]+ calcd for C10H18N4O2: 
249.1430; found: 249.1427.
Compound 4k: Yield: 78%; yellowish gum; [α]D25 –20.5 (c 
1.0, CHCl3); Rf = 0.4 (CHCl3–MeOH, 9:1); IR (neat): 1747, 
1762, 2881, 3432 cm–1; 1H NMR (CDCl3, 400 MHz): δ = 
0.98 (d, J = 6.3 Hz, 6 H), 1.61–1.63 (m, 2 H), 1.70 (m, 1 H), 
2.43–2.54 (s, 1 H), 4.82 (br, 2 H), 5.25 (s, 2 H), 4.50 (t, J = 
5.6 Hz, 1 H), 5.34 (s, 2 H), 5.8 (s, 1 H), 6.50 (br, 1 H), 7.11–
7.23 (m, 5 H), 10.11 (br, 1 H); 13C NMR (CDCl3, 100 MHz): δ = 19.3, 21.1, 38.9, 49.6, 52.3, 65.1, 65.9, 93.2, 125.7, 
127.3, 128.2, 139.9, 142.1, 154.2, 155.8, 169.3; HRMS: m/z 
[M + Na]+ calcd for C19H27N5O4: 412.1961; found: 412.1963
(32) Chiral HPLC details: Agilent 1100 series having G1311A 
VWD at λ = 230 nm; flow 1.0 mL/min; Column: 
Phenominex made Lux; pore size 5 μm; Cellusole-1, 
250 × 4.6 mm; n-hexane–isopropanol (85:15) in isocratic 
mode in 40 min
(33) Dressen, D.; Garofalo, A. W.; Hawkinson, J.; Hom, D.; 
Jagodzinski, J.; Marugg, J. L.; Neitzel, M. L.; Pleiss, M. A.; 
Szoke, B.; Tung, J. S.; Wone, D. W. G.; Wu, J.; Zhang, H. 
J. Med. Chem. 2007, 50, 5161.
(34) Černovská, K.; Kemter, M.; Gallmeier, H.-C.; Rzepecki, P.; 
Schrader, T.; König, B. Org. Biomol. Chem. 2004, 2, 1603.
(35) Sureshbabu, V. V.; Hemantha, H. P. ARKIVOC 2008, (ii), 
243.
(36) Preparation of Pyrazole-Linked Peptidomimetic 6a; 
Typical Procedure: To a solution of Fmoc-Val-Cl (0.5 
mmol, 0.2 g) and NMM (0.68 mmol, 0.07 mL) in THF at 
0 °C, was added Cbz-protected-Ala-5-amino-pyrazole. The 
reaction mixture was stirred for 2–3 h (TLC monitoring). 
After completion of reaction, the solvent was removed under 
reduced pressure and the residue was dissolved in EtOAc (10 
mL), washed with citric acid (10%, 10 mL), aqueous 
Na2CO3 (10%, 10 mL), H2O (2 × 10 mL), and brine (2 × 10 
mL). The organic phase was dried over anhydrous Na2SO4 
and then concentrated under reduced pressure. The residue 
was purification by column chromatography (silica gel 100–
200 mesh; CHCl3–MeOH, 9:1) to afford 
pyrazolecarboxamides.
Compound 6a: Yield: 78%; yellowish solid; [α]D25 +52.7 (c 
1.0, CHCl3); Rf = 0.3 (CHCl3–MeOH, 9:1); IR (neat): 1659, 
1766, 2886, 3423 cm–1; 1H NMR (CDCl3, 400 MHz): δ = 
0.99 (m, 6 H), 1.30 (d, J = 4.5 Hz, 3 H), 2.01 (m, 1 H), 4.19 
(d, J = 3.9 Hz, 1 H), 4.20 (t, J = 6.6 Hz, 1 H), 4.21 (d, J = 
7.4 Hz, 2 H), 4.82 (m, 1 H), 5.01 (s, 2 H), 5.18 (m, 2 H), 5.89 
(s, 1 H), 6.09 (br, 2 H), 7.25–7.77 (m, 13 H), 11.8 (br, 1 H); 
13C NMR (CDCl3, 100 MHz): δ = 16.1, 20.2, 28.0, 42.4, 
46.2, 47.5, 52.0, 58.1, 64.9, 66.8, 91.3, 124.6, 125.3, 126.1, 
126.8, 127.0, 128.4, 136.1, 139.3, 140.2, 141.6, 143.0, 
155.3, 155.5, 170.1; HRMS: m/z [M + Na]+ calcd for 
C33H35N5O5: 604.2536; found: 604.2538.
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